Oxybuprocaine | CAS#99-43-4

MedKoo Cat#: 318404 | Name: Oxybuprocaine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Oxybuprocaine is an ester-type local anesthetic that is used especially in ophthalmology and otolaryngology. Oxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions.

Chemical Structure

Oxybuprocaine

CAS#99-43-4 (free base)

Theoretical Analysis

MedKoo Cat#: 318404

Name: Oxybuprocaine

CAS#: 99-43-4 (free base)

Chemical Formula: C17H28N2O3

Exact Mass: 308.2100

Molecular Weight: 308.42

Elemental Analysis: C, 66.20; H, 9.15; N, 9.08; O, 15.56

Price and Availability

Size	Price	Availability	Quantity
250mg	USD 350.00	2 Weeks
1g	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

99-43-4 (free base) 5987-82-6 (HCl)

Synonym

Oxybuprocaine, Benoxinate, BNX, Butoxyprocaine, Novescine, Novesin

IUPAC/Chemical Name

2-(diethylamino)ethyl 4-amino-3-butoxybenzoate

InChi Key

CMHHMUWAYWTMGS-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3

SMILES Code

O=C(OCCN(CC)CC)C1=CC=C(N)C(OCCCC)=C1

Appearance

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 308.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Little WB, Jean GS, Sithole F, Little E, Jean KY. Degree of corneal anaesthesia after topical application of 0.4% oxybuprocaine hydrochloride and 0.5% proparacaine hydrochloride ophthalmic solution in clinically normal cattle. Aust Vet J. 2016 Jun;94(6):181-5. doi: 10.1111/avj.12443. PubMed PMID: 27237118. 2: Giudici V, Baeza S, Douet JY, Regnier A. Corneal anesthesia following application of 0.4% oxybuprocaine hydrochloride ophthalmic solution to normal feline eyes. Vet Ophthalmol. 2015 Mar;18(2):141-6. doi: 10.1111/vop.12179. Epub 2014 May 14. PubMed PMID: 24824864. 3: Fernandez-Garcia P, Cerviño A, Quiles-Guiñau L, Albarran-Diego C, Garcia-Lazaro S, Sanchis-Gimeno JA. Corneal thickness differences between sexes after oxybuprocaine eye drops. Optom Vis Sci. 2015 Jan;92(1):89-94. doi: 10.1097/OPX.0000000000000449. PubMed PMID: 25360701. 4: Douet JY, Michel J, Regnier A. Degree and duration of corneal anesthesia after topical application of 0.4% oxybuprocaine hydrochloride ophthalmic solution in ophthalmically normal dogs. Am J Vet Res. 2013 Oct;74(10):1321-6. doi: 10.2460/ajvr.74.10.1321. PubMed PMID: 24066916. 5: Ansari H, Weinberg L, Spencer N. Toxic epitheliopathy from a single application of preservative free oxybuprocaine (0.4%) in a patient with Sjogren's syndrome. BMJ Case Rep. 2013 Sep 13;2013. pii: bcr2013010487. doi: 10.1136/bcr-2013-010487. PubMed PMID: 24038291; PubMed Central PMCID: PMC3794119. 6: Almubrad TM, Alshehri FH, Ogbuehi KC, Osuagwu UL. Comparison of the influence of nonpreserved oxybuprocaine and a preserved artificial tear (thera tears) on human corneal thickness measured by two pachymeters. J Ocul Pharmacol Ther. 2013 Jun;29(5):462-8. doi: 10.1089/jop.2012.0215. Epub 2013 Jan 18. PubMed PMID: 23331053. 7: Ogbuehi KC, Chijuka JC, Osuagwu UL. Changes in central corneal thickness values after instillation of oxybuprocaine hydrochloride 0.4%. Cont Lens Anterior Eye. 2012 Oct;35(5):199-202. doi: 10.1016/j.clae.2012.05.004. Epub 2012 Jun 15. PubMed PMID: 22704944. 8: Chen YW, Chu CC, Chen YC, Hung CH, Hsueh MI, Wang JJ. Clonidine as adjuvant for oxybuprocaine, bupivacaine or dextrorphan has a significant peripheral action in intensifying and prolonging analgesia in response to local dorsal cutaneous noxious pinprick in rats. Neurosci Lett. 2011 Jun 8;496(3):186-90. doi: 10.1016/j.neulet.2011.04.021. Epub 2011 Apr 17. PubMed PMID: 21524685. 9: Rosa N, De Bernardo M, Borrelli M, Filosa ML, Lanza M. Effect of oxybuprocaine eye drops on corneal volume and thickness measurements. Optom Vis Sci. 2011 May;88(5):640-4. doi: 10.1097/OPX.0b013e3182114303. PubMed PMID: 21358446. 10: Hung CH, Liu KS, Shao DZ, Cheng KI, Chen YC, Chen YW. The systemic toxicity of equipotent proxymetacaine, oxybuprocaine, and bupivacaine during continuous intravenous infusion in rats. Anesth Analg. 2010 Jan 1;110(1):238-42. doi: 10.1213/ANE.0b013e3181bf6acf. Epub 2009 Nov 6. PubMed PMID: 19897799. 11: Hung CH, Wang JJ, Chen YC, Chu CC, Chen YW. Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats. Neurosci Lett. 2009 May 1;454(3):249-53. doi: 10.1016/j.neulet.2009.03.018. Epub 2009 Mar 11. PubMed PMID: 19429093. 12: Díaz-Rey JA, Giráldez MJ, García-Resúa C, Yebra-Pimentel E. [Effect of double anaesthetic Colicursi (tetracaine 0.1% and oxybuprocaine 0.4%) on central and paracentral corneal thickness]. Arch Soc Esp Oftalmol. 2009 Jan;84(1):23-30. Spanish. PubMed PMID: 19173135. 13: Nam SM, Lee HK, Kim EK, Seo KY. Comparison of corneal thickness after the instillation of topical anesthetics: proparacaine versus oxybuprocaine. Cornea. 2006 Jan;25(1):51-4. PubMed PMID: 16331042. 14: Asensio I, Rahhal SM, Alonso L, Palanca-Sanfrancisco JM, Sanchis-Gimeno JA. Corneal thickness values before and after oxybuprocaine 0.4% eye drops. Cornea. 2003 Aug;22(6):527-32. PubMed PMID: 12883345. 15: Blaschke V, Fuchs T. Periorbital allergic contact dermatitis from oxybuprocaine. Contact Dermatitis. 2001 Mar;44(3):198. PubMed PMID: 11218008. 16: Kuhlmann O, Stoldt G, Struck HG, Krauss GJ. Simultaneous determination of diclofenac and oxybuprocaine in human aqueous humor with HPLC and electrochemical detection. J Pharm Biomed Anal. 1998 Sep;17(8):1351-6. PubMed PMID: 9800654. 17: Anding K, Albrecht P, Heilmann C, Daschner F. [The bactericidal effect of oxybuprocaine. A possible cause of false negative results in bronchoalveolar lavage]. Anaesthesist. 1993 Sep;42(9):619-22. German. PubMed PMID: 8214534. 18: Lytle J, Thomas NF. Haemodynamic stability during general anaesthesia for intra-ocular surgery: the effect of topical oxybuprocaine. Anaesthesia. 1992 Jul;47(7):616-7. PubMed PMID: 1626678. 19: Cruysberg JR. [Oxybuprocaine drops and eyedrops should not be given to patientson prescription]. Ned Tijdschr Geneeskd. 1990 Sep 29;134(39):1910. Dutch. PubMed PMID: 2215773. 20: Christensen C. Bradycardia as a side-effect to oxybuprocaine. Acta Anaesthesiol Scand. 1990 Feb;34(2):165-6. PubMed PMID: 2305619.